Legend Biotech Projects 2026 Operating Profit Amid Strong CARVYKTI® Growth and Pipeline Progress
summarizeSummary
Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.
check_boxKey Events
-
Projected Profitability
The company expects to achieve company-wide operating profit in 2026, marking a significant financial inflection point.
-
CARVYKTI® Market Leadership
CARVYKTI® has treated over 10,000 patients, achieved NCCN Category 1 designation, and boasts a 10,000 annualized dose capacity by 2026.
-
Pipeline Advancement
Patients have been dosed for IIT In Vivo CAR-T studies in 2025, with plans to file 1-2 US INDs in the second half of 2026.
-
Manufacturing Scale-Up
All CARVYKTI® manufacturing sites are now online, with a 97% success rate and a median turnaround time of less than 30 days.
auto_awesomeAnalysis
Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.
この提出時点で、LEGNは$23.32で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$41.7億でした。 52週の取引レンジは$20.21から$45.30でした。 この提出書類はポジティブの市場センチメント、重要度スコア8/10と評価されました。